null

null

null

null

null

null

null

null

null

null

null

null

null

Pre-revenue biotech; primarily equity-financed with ~$300M+ raised; minimal long-term debt; 20% rate rise negligibly impacts interest expense but tightens future fundraising conditions

High indirect sensitivity; as a loss-making biotech dependent on venture/equity capital, rising rates compress valuation multiples and increase cost of future capital rounds significantly

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) Illumina sequencing platform monopoly for NGS reagents/instruments; 2) Taiwanese semiconductor fabs for AI/ML compute hardware used in bioinformatics pipeline

Primarily US-focused pre-commercialization; negligible international revenue; sovereign currency devaluation exposure is near-zero currently but relevant post-commercialization in EU/Japan

Operations concentrated in South San Francisco, CA; no material international revenue markets identified; geographic footprint is single-country, limiting currency devaluation exposure

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Critical non-substitutable dependency on Illumina NGS platforms (>30% operational input); switching to PacBio/Oxford Nanopore would require significant revalidation and regulatory re-filing

Cloud migration risk is HIGH; Freenome's ML/AI genomic analysis pipelines are deeply cloud-integrated; 30-day termination would halt computational workflows and delay diagnostic development by 6-12 months

B2B diagnostics/healthcare SaaS hybrid; licensing early-detection assay results to health systems and partnering with pharma companies for biomarker discovery

High API coupling risk to Illumina's BaseSpace and proprietary bioinformatics APIs; replatforming would require 12-24 months of revalidation and FDA analytical validation updates

Low Howey Test risk; revenue model based on diagnostic test reimbursement and pharma partnerships, not investment contracts; no tokenized or profit-sharing instruments identified

Very High

Moderate-high HIPAA exposure as primary concern; GDPR risk low currently given US focus; CCPA compliance required for California patient genomic data—genomic data classification as sensitive adds regulatory complexity

Low direct antitrust risk; early-stage market entrant in liquid biopsy; however, any exclusive dealing arrangement with Illumina or major health systems could attract FTC scrutiny post-commercialization

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Pre-commercial; ~100% revenue from pharma partnerships/research collaborations (milestone-based); negligible recurring diagnostic reimbursement revenue as of 2024

Dual vector: 1) B2B pharma partnership milestones for biomarker discovery; 2) planned B2B2C clinical diagnostic reimbursement via CMS/private insurers post-FDA approval

Pricing architecture unproven at scale; test reimbursement likely $300-$500/test (comparable to Guardant/Foundation Medicine); stressed by CMS reimbursement rate compression risk under PAMA

Moderate-low near-term; reimbursement rates set by CMS/insurers, not Freenome; pricing power improves significantly post-FDA approval with clinical utility data demonstrating superior sensitivity/specificity

Target gross margin 60-70% at scale (consistent with liquid biopsy peers Guardant Health ~65%); currently negative gross margin in development phase

No free-rider problem currently; pharma partnership model requires paid contracts; post-commercialization, physician ordering behavior could create volume volatility if reimbursement coverage is inconsistent

Revenue growth will be sublinear to headcount post-commercialization; lab processing and AI inference scale with automation; however, regulatory/clinical affairs headcount scales linearly in early phases

Marginal cost of growth decreasing long-term as AI/ML models improve with data volume; near-term growth requires lab capacity capex and regulatory headcount, making it moderately capital-intensive

Not applicable; Freenome does not operate a franchise model

At 10x scale, CAC should decline as clinical evidence accumulates and guideline inclusion (NCCN/ACS) drives organic physician adoption; estimated CAC $150-300/ordering physician at scale

Weak direct network effects; strong data network effect—each additional sample improves ML model accuracy, creating compounding competitive moat as dataset scale increases

AI displacement risk is paradoxically positive; Freenome's core value IS AI-driven diagnostics; risk is that better-funded competitors (Grail, Guardant) deploy superior AI models faster

Moderate recession resistance; cancer screening demand is relatively inelastic but elective screening compliance drops in recessions; reimbursement-based model insulates somewhat from consumer spending cuts

Health systems and oncology clinics (ordering physicians); concentration risk high pre-scale as early commercial launch will depend on handful of academic medical center partnerships

Pharmaceutical companies (AstraZeneca partnership confirmed); pharma segment provides milestone revenue concentration risk—loss of one major pharma partner could reduce revenue 30-50% currently

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital is being deployed toward future-state infrastructure: CLIA-certified lab expansion, AI/ML compute, and clinical trial investment; minimal legacy asset reallocation burden

null

null